News & Updates

Show Multimedia Only

POSEIDON: Dual ICIs plus chemo up survival in first-line mNSCLC

20 Jan 2023 by

Adding two immune checkpoint inhibitors, tremelimumab (T) and durvalumab (D), to platinum-based chemotherapy (CT) significantly improves overall survival (OS) and progression-free survival (PFS) vs CT alone in first-line treatment of metastatic non-small-cell lung cancer (mNSCLC), without causing a meaningful increase in toxicity, according to results of the phase III POSEIDON trial.

20 Jan 2023

Lung cancer ups mortality risk in IPF patients

19 Jan 2023

A diagnosis of lung cancer can significantly worsen survival in patients with idiopathic pulmonary fibrosis (IPF), reports a study.

19 Jan 2023

MRI- vs CT- guided radiotherapy for localized prostate cancer linked to lower toxicity, symptom burden

19 Jan 2023 by

Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.

19 Jan 2023

Digital misinformation may lead to wrong health decisions, says study

18 Jan 2023 by

An online cross-sectional survey involving antivaxxers, conspiracy theorists, and flat earthers reveals how these people are more likely to believe in false causes of cancer, indicating an association between digital misinformation and consequent erroneous health decisions.

18 Jan 2023

START-FIT: TACE + RT + avelumab promising as conversion therapy for locally advanced unresectable HCC

18 Jan 2023 by

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.

18 Jan 2023

$Cancer survivors at risk of fractures$

Cancer survivors at risk of fractures

17 Jan 2023 by

Cancer survivors may have an elevated risk of frailty fractures, particularly in the first few years following cancer diagnosis, according to results of a recent study from the US.

17 Jan 2023

Original New Drug Application Approvals by US FDA (01-15 January 2023)

17 Jan 2023

New drug applications approved by US FDA as of 01-15 January 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

17 Jan 2023

Guided bronchoscopy falls short of improving diagnostic yield for peripheral pulmonary lesions

16 Jan 2023

Advances in bronchoscopic technology have been increasingly applied for diagnosing peripheral pulmonary lesions, but a recent study has found that such advances have not translated to improved diagnostic yield.

16 Jan 2023